

Supplementary Table 4. Baseline and Clinical Characteristics of Patients with Other Common Bacterial, Atypical Pathogen, or Viral Infections

Patient ID	Sex (0=M,1=F)	Age at onset (mo)	Age at first RTX (mo)	Disease duration before RTX (mo)	Clinical diagnosis	Renal biopsy	IVIg use, 1 yr pre-RTX	Baseline CD19 (cells/ μ L)	Baseline IgG (g/L)	Baseline IgE (IU/mL)	6mo CD19 (cells/ μ L)	6mo IgG (g/L)	6mo IgE (IU/mL)	Concomitant immunosuppressants	Pathogen type	Time of infection detection	Liver dysfunction	Renal dysfunction	Relapses within 1 yr after RTX
#1	0	29.5	64	34.5	SSNS+FRNS	NA	YES	190.665	5.45	38.2	58.09	7.01	36.4	GC+TAC	M. catarrhalis	6mo	NO	NO	0
#2	1	61	147	86	SRNS+FRNS	MCD	NO	120.571	3.21	61.7	2.35	7.02	23.1	GC+TAC	S. pneumoniae	6mo	NO	YES	0
#3	1	23	101	78	SRNS+FRNS	MCD	YES	636.104	5.63	4640	57.28	6.2	1280	GC+TAC	S. pneumoniae	6mo	NO	YES	1
#4	0	51.3	58.9	7.6	SRNS+FRNS	FSGS	YES	1281.88	2.58	2080	7.79	4.6	77.7	GC+TAC	M. pneumoniae	6mo	NO	YES	0
#5	0	18	80	62	SSNS	NA	YES	477.62	6.92	85.5	234.99	9.61	36.6	GC	M. pneumoniae	12mo	NO	NO	0
#6	0	24.2	60.4	36.2	SSNS	NA	YES	269.724	7.87	6.2	240.36	8.76	5.4	GC	M. pneumoniae	12mo	NO	NO	0
#7	1	64.8	135	70.2	SSNS	NA	YES	452.561	3.63	17.4	73.123	5.36	7	GC	M. pneumoniae+H. influenzae	12mo	NO	NO	0
#8	0	35.7	60.1	24.4	SRNS	NA	YES	381.546	4.17	1600	143.9	8.21	206	GC+TAC	S. pneumoniae	12mo	NO	NO	0
#9	0	150.7	159.3	8.6	SSNS+FRNS	NA	YES	159.39	7.28	367	53.607	7.13	220	GC+TAC	E. coli	12mo	NO	YES	0
#10	1	19	80	62.5	SSNS	NA	YES	345.43	4.31	64.2	341.65	7.12	16.4	NO	M. pneumoniae+IFV	12mo	NO	NO	0
#11	1	36.5	92.7	56.2	SSNS+FRNS	NA	YES	196.308	7.09	12	114.59	7.8	8.6	GC+TAC	M. pneumoniae+IFV	12mo	NO	YES	0
#12	1	20	108.6	88.6	SRNS+FRNS	NA	YES	196.01	6.92	7	551.57	11.1	<5	GC+TAC	M. pneumoniae+H. influenzae+AdV	12mo	NO	NO	0
#13	0	19.5	79.4	59.9	SRNS	NA	YES	315.368	5.71	30.7	239.86	2.11	30	GC+TAC	VZV	6mo	NO	NO	2
#14	1	112.7	114.9	2.2	SSNS	MCD	YES	466.804	4.65	151	3.06	5.89	23.6	GC	COVID-19	6mo	NO	NO	2
#15	1	65	92.1	27.1	SSNS+FRNS	NA	YES	417.04	8.08	34.4	71.95	7.38	20.8	GC+TAC	IFV	6mo	NO	YES	0
#16	0	50.2	83.2	33	SRNS+FRNS	NA	YES	1380.09	5.95	227	326.112	8.91	269	GC+TAC	IFV+COVID-19	6mo	NO	NO	1
#17	1	42.7	84	41.3	SRNS+FRNS	NA	YES	266.175	3.37	111	4.256	5.99	13.3	GC+TAC	IFV	6mo	NO	NO	0
#18	1	17	137	120	SRNS+FRNS	NA	YES	1283.433	7.84	18.5	145.95	5.26	<5	GC+TAC	IFV	6mo	NO	YES	0
#19	1	52.5	100.8	48.3	SRNS	MCD	YES	857.2	9.87	7.7	200.67	11.7	10.1	TAC	IFV	12mo	NO	NO	0
#20	1	88.4	107.8	19.4	SRNS+FRNS	MCD	YES	752.955	0.73	98.7	1.529	1.45	177	GC+TAC	IFV+COVID-19	12mo	NO	YES	1
#21	1	18.6	63.9	45.3	SRNS+FRNS	NA	YES	641.2	6.66	26.5	102.39	6.35	9.7	GC+TAC	IFV	12mo	NO	NO	0
#22	0	39	67.7	28.7	SRNS+FRNS	MCD	YES	182.665	3.18	5348	296.16	2.32	2280	GC+TAC	IFV	12mo	NO	YES	2

Infection was defined as at least one documented episode of common bacterial(excluding M. tuberculosis), atypical pathogen, or viral(excluding EBV, CMV and HBV) infection within 12 months after RTX infusion.

Abbreviations: RTX, rituximab; SSNS, steroid-sensitive nephrotic syndrome; SRNS, steroid-resistant nephrotic syndrome; MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; IVIG, intravenous immunoglobulin; GC, glucocorticoid; TAC, tacrolimus; IgG, immunoglobulin G; IgE, immunoglobulin E.